Product Description
Furosemide is in a class of medications called diuretics ('water pills'). It works by causing the kidneys to get rid of unneeded water and salt from the body into the urine. urosemide is used alone or in combination with other medications to treat high blood pressure. Furosemide is used to treat edema (fluid retention; excess fluid held in body tissues) caused by various medical problems, including heart, kidney, and liver disease. (Sourced from: https://medlineplus.gov/druginfo/meds/a682858.html)
Mechanisms of Action: NKCC Inhibitor, TGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Mannkind
Company Location: Eastern America
Company CEO: Michael E. Castagna
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Czech Republic, Denmark, Germany, United Kingdom, United States
Active Clinical Trial Count: 13
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pain Unspecified
Phase 2: Adenocarcinoma|Dyspnea|Heart Failure|Prostate Cancer
Phase 1: Healthy Volunteers|Malaria
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-514672-41-00 |
INFURO_2023 | P2 |
Recruiting |
Dyspnea |
2026-01-01 |
2025-05-02 |
Treatments |
|
NCT05779943 |
STUDY00004720 | P2 |
Active, not recruiting |
Prostate Cancer|Adenocarcinoma |
2024-03-15 |
12% |
2025-10-28 |
Primary Completion Date|Primary Endpoints|Treatments |
ACTRN12621001218886 |
ACTRN12621001218886 | P1 |
Completed |
Malaria |
2023-01-18 |
2024-08-29 |
Treatments |
|
2024-510792-38-01 |
2024-510792-38-01 | P3 |
Withdrawn |
Pain Unspecified |
2029-03-01 |
2025-05-02 |
Treatments |
|
NCT06167707 |
scP-04-001 | P1 |
Completed |
Heart Failure |
2024-06-14 |
12% |
2024-06-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20230743 |
CTR20230743 | P1 |
Completed |
Healthy Volunteers |
2024-02-02 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05768360 |
D5084C00014 | P1 |
Completed |
Healthy Volunteers |
2023-06-24 |
23% |
2023-07-14 |
|
NCT05528588 |
RESISTANCE-HF | P2 |
Completed |
Heart Failure |
2024-04-22 |
50% |
2024-12-19 |
Primary Endpoints|Study Completion Date |
2024-510792-38-00 |
2024-510792-38-00 | P3 |
Withdrawn |
Pain Unspecified |
2029-03-01 |
2025-05-02 |
Treatments |
|
NCT07269496 |
SQI-01-03 | P1 |
Not yet recruiting |
Healthy Volunteers |
2026-02-15 |
88% |
2025-12-11 |
Primary Endpoints |
NCT07073157 |
HRS-8427-106 | P1 |
Completed |
Healthy Volunteers |
2025-08-15 |
50% |
2025-08-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06491550 |
D9440C00002 | P1 |
Completed |
Healthy Volunteers |
2025-06-11 |
50% |
2025-07-08 |
Primary Endpoints |
NCT06504862 |
U1111-1302-1171 | P1 |
Completed |
Healthy Volunteers |
2024-10-03 |
50% |
2026-01-10 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/19/2026 |
News Article |
FDA approves first drug to delay the onset of congestive heart failure in dogs |
|
01/09/2026 |
News Article |
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference |
|
01/08/2026 |
News Article |
MannKind Provides Business Updates and 2026 Growth Drivers |
|
12/30/2025 |
News Article |
Tellihealth Enters 2026 as a Leading Force in Remote Care After a Year of Record Patient Impact and Clinical Innovation |